FLYSYN

Drug Profile

FLYSYN

Alternative Names: 4G8-SDIEM

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synimmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 01 Feb 2017 Phase-I/II clinical trials in Acute myeloid leukaemia (Monotherapy) in Germany (IV) (NCT02789254)
  • 13 May 2016 Synimmune plans a phase Ib/IIa trial for Acute myeloid leukaemia in Germany (NCT02789254)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top